CCR Anniversary Commentaries
Paving the Way for Circulating Tumor Cells (Allard and Terstappen)
Chimeric Antigen Receptors—From Model T to the Tesla (Hwu)
Divide and Conquer—Breast Cancer Subtypes and Response to Therapy (Pusztal, Rouzier, and Symmans)
RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer—From Concept to Practice (Camp and Ellis)
From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research (Wolf and Wolf)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Mok et al. Clinical Cancer Research.
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Eberlein et al. Cancer Research.